All stock lists
Lufax Holding Ltd (New York Stock Exchange:LU)
CN · Delayed Price · Currency is USD
Financial Services · Financial - Credit Services
8.48+0.42 (+5.21%)
Market cap
$7.35B
Health Score
Analyst consensus
Listed since
Oct 30, 2020
Website
Insider Score
––Not scored
LU Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Sound
From LU’s reported statements · Q2 2026 (trailing 12 months)
Profitability6 / 20
Loses money on what it sells.
- Revenue
- $28.40B
- Net income
- -$2.23B
- Net margin
- -7.8%
Leverage0 / 20
Heavily indebted for what it earns.
- Total debt
- $72.54B
- Cash
- $19.21B
- Net debt / EBITDA
- 5.92x
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $175.31B
- Current liabilities
- $5.07B
- Current ratio
- 34.60
Cash generation20 / 20
The business funds itself from operations.
- Operating cash flow
- $12723.37B
- Free cash flow
- $12672.06B
- FCF margin
- 44621.4%
Dilution & runway20 / 20
Not funding itself by issuing shares.
- Shares outstanding
- 430.7M
- Share growth (1y)
- -0.7%
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
LU Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 6.24 B | 6.24 B | 7.95 B | 7.95 B | 6.36 B | 7.04 B |
| Revenue Growth (YoY) | -1.77 % | -11.33 % | -19.49 % | 78.88 % | 6.37 % | 1.13 % |
| Cost of Revenue | 883.67 M | 883.67 M | 5.36 B | 5.36 B | 4.32 B | 1.02 B |
| Gross Profit | 5.36 B | 5.36 B | 2.59 B | 2.59 B | 2.03 B | 6.02 B |
| SG&A Expense | 964.14 M | 5.66 B | 2.12 B | 2.12 B | 1.48 B | 5.70 B |
| R&D Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.66 B | 5.66 B | 2.12 B | 2.12 B | 1.77 B | 5.70 B |
| Operating Income | -297.59 M | -297.59 M | 469.37 M | 469.37 M | 266.47 M | 318.61 M |
| Pretax Income | -342.73 M | -342.73 M | -534.35 M | -534.35 M | 266.47 M | 245.48 M |
| Tax Provision | 4.40 M | 4.40 M | 61.97 M | 61.97 M | 860.67 M | 504.97 M |
| Net Income | -447.94 M | -447.94 M | -665.22 M | -665.22 M | -711.52 M | -383.62 M |
| EPS (Basic) | -1.04 | -1.04 | -1.54 | -1.54 | -1.64 | -0.88 |
| EPS (Diluted) | -1.04 | -1.04 | -1.54 | -1.54 | -1.64 | -0.88 |
| Shares Outstanding | 430.72 M | 430.72 M | 431.96 M | 431.96 M | 433.86 M | 433.34 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.